News Library


Recommendations for the treatment of stable angina pectoris with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction, ESC 2016 .

“Trimetazidine may be considered when angina persists despite treatment with a beta-blocker (or alternative) to relieve angina (effective anti-anginal treatment, safe in HF)” .

Class IIb Level A.

Ref.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, doi:10.1093/eurheartj/ehw128


The update to the 2013 ACCF/AHA Guideline for the Management of Heart Failure includes the addition of sinoatrial node modulator, ivabradine* to the list of treatment options for Stage C heart failure patients with a reduced ejection fraction..

*Ivabradine is marketed in India under the brand name of Coralan® 5mg and 7.5mg.

Reference.: AHA / ASA newsroom with title “Societies Release Guideline Update for Heart Failure Therapies”(


The latest hypertension guidelines recommend initiating with a thiazide-like diuretic (such as Natrilix® SR - indapamide SR 1.5mg) or a calcium channel blocker or their combination (such as Natrilam® 2.5, 5 or 10 - indapamide SR 1.5mg with amlodipine 2.5mg / 5mg / 10 mg), particularly for hypertensive patients above 50 years of age, as systolic blood pressure (SBP) appears to be a better predictor of cardiovascular events than the diastolic blood pressure (DBP) after the age of 50 years.

ESH-ESC 2013 Hypertension guidelines : J of Hypertension 2013 : 31:7:1317; JNC 8 panel recommendations: JAMA 2014;311(5):507-520; ACC-AHA-CDC Science Advisory 2013: Hypertension 2014;63:878-885;
ASH-ISH guidelines: J of Hypertension 2014;32:3-15


Intensive glucose control with gliclazide extended release regimen was associated with a long term reduction in End Stage Kidney Disease (ESKD). This is the strongest evidence to date regarding renal benefits with glucose lowering therapies..

Ref :- Wong, Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON; Diabetes Care, March 2016, DOI: 10.2337/dc15-2322, Pg 1-15


The largest reduction in all-cause mortality in hypertensive population occurred in trials of Coversyl® (Perindopril).

Expert Rev.Cardiovasc.Ther.2013;11(6):705-717.


The latest American Diabetic Association 2016 guideline refers to ADVANCE BPLA stating the active blood pressure intervention arm (a single-pill, fixed-dose combination of perindopril and indapamide-Coversyl® Plus & Coversyl® Plus HD) showed a significant reduction in the risk of the primary composite end point (major macrovascular or microvascular events) and a significant reduction in the risk of death from any cause and of death from cardiovascular causes.

American Diabetes Association (ADA). Standards of medical care in diabetes.
Diabetes Care 2016;39(suppl 1):S60-71.


The latest ESC/ESH guidelines recommend Coversyl® AM (Perindopril + Amlodipine) as the preferred combination for the treatment of hypertensive patients with CAD.

ESH-ESC 2013 Hypertension guidelines: J of Hypertension 2013;31:1281-1357

Daflon® 1000mg

The 1st Indian consensus statement on chronic venous disease acclaims MPFF* as the drug with maximum evidence and strongly recommended in all stages of chronic venous disease. .

* Micronized Purified Flavonoid Fraction (marketed as daflon® 1000mg in India).

Consensus presented at Venous Association of India Conference 11th Feb 2016, Jaipur, India